Ann: Notice of Annual General Meeting/Proxy Form , page-75

re: Ann: Notice of Annual General Meeting/Pro... Hi cmk,

"I would very much like you to spell it out for me as it is not very obvious to me......are you suggesting that this has been positioned so that shareholders won't take-up a Rights Issue & maybe the shortfall go to a Broker to P&D or could it be a requirement from a FMCG to position itself as a cornerstone investor & place itself in a takeover position?!?"

None of the above mate. There has been so much negative sentiment on these threads to help promote a descending sp in recent times that it becomes somewhat futile in attempt to add anything of substance or real value on the threads. My apologies for the late reply, but I came to realise soon after open that the answer wasn't so obvious, and that opportunities also present themselves when something like, new ASX rules to Chapter 7 create unnecessary panic selling. My words were not intended to insult any person here, but these new rules became effective August 2012 and apply to all small and mid-cap companies with a market capitalisation of $300 million or less.

I would expect to see most eligible companies take advantage of the changes as it will reduce placement compliance costs, whether a company uses the facility or not.

When we have a market which continue to ignore the fundamental growth of a company and the significant interest and progress being reported by its current and potential global partners, the technical indicators which are only formed on the principles of market psychology, as we were witness to yesterday are nothing more than noise, which hardly provides any credibility in terms of assessing the true value of any stock.

We must also keep in mind that all three of our directors have invested a considerable amount of their own funds into this company over a number of years which demonstrates their own long term commitment towards the future of the company. Each of their own individual holdings would total more than what many of us here have committed to, and like both you and I, one may assume that they would also be sitting under water at this time, but as the fundamentals haven't changed we should be sleeping peacefully at night.

Long term investors only need reminding of the expertise and experience the collective management team brings to the company in order to truly appreciate that the only strange thing about this company right now is indeed its share price...

- Over 30 years experience working for some of the world’s leading pharmaceutical, FMCG and cosmetic companies.

- Conducted numerous clinical trials for a number of international pharmaceutical companies including, Roche, Novartis, Matrix (Mylan) and 3M.

- Served on advisory boards for some of the largest pharmaceutical companies in the world including, Sandoz, Novartis, Roche, Merck Sharpe and Dohme, Allergan, Wyeth and Johnson & Johnson.

- Managed new product innovations and licensing deals for some of the leading Pharmaceutical and FMCG companies in the world, including, GlaxoSmithKline, Unilever, CB Fleet, PZ Cussons and Reckitt Benckiser.

"True innovation is becoming increasingly rare with regulatory barriers and increasing costs leading to more standardised products. OBJ’s physical rather than chemical approach to product performance enhancement may change the balance in established product categories.” - Dr. Kevin Hammond - former partnering, licensing and new product innovations for majors, including, Reckitt Benckiser, Unilever, and GSK.
__________

Hi Amo,

"OBJ is using the partner-funded programs to prove-up products and innovations and utilize its resources to broaden its commercial base and reduce sole reliance on the time-frames of its partners."

"The treatment and/or prevention of musculoskeletal pain remains an area where OBJ believes its technology offers potential unique benefits. The ultimate aim of this program will be to develop at least one product to marketable status, such that OBJ has the choice of offering a supported finished product to an established brand partner, or launching the product directly into the market through a distribution partnership."